Table 5.

MOAS subdomain scores

Outcome	Time point	Placebo		Risperidone
		N	Summary	N	Summary
MOAS patient rating	Baseline*	7	4.7±2.4	5	3.4±1.7
Verbal	Week 12	7	1.4±1.3	5	1.0±1.4
	Change†	7	−3.3±2.7	5	−2.4±2.3
MOAS patient rating	Baseline*	7	2.0±2.1	5	0.2±0.4
Against property	Week 12	7	0.3±0.8	5	0.2±0.4
	Change†	7	−1.7±2.4	5	0.0±0.0
MOAS patient rating	Baseline*	7	0.6±0.8	5	0.4±0.9
Autoaggression	Week 12	7	0.0±0.0	5	0.0±0.0
	Change†	7	−0.6±0.8	5	−0.4±0.9
MOAS patient rating	Baseline*	7	0.3±0.8	5	0.0±0.0
Against people	Week 12	7	0.0±0.0	5	0.2±0.4
	Change†	7	−0.3±0.8	5	0.2±0.4
MOAS carer rating	Baseline*	5	8.4±8.4	3	10.3±6.5
Total score	Week 12	5	2.8±3.1	3	3.7±3.8
	Change†	5	−5.6±5.6	3	−6.7±3.2

*Summary statistics only for patients with values at 12 weeks.

†Calculated as value at week 12 minus value at baseline.

MOAS, Modified Overt Aggression Scale.